Thinking about HDAC2

Rodin's safe, selective HDAC2 inhibitors for AD

Rodin Therapeutics Inc. is developing selective HDAC2 inhibitors to treat cognitive impairment in Alzheimer's disease (AD) without causing the serious side effects associated with pan-HDAC - a strategy that netted it a deal with Biogen Inc. in January worth up to $485 million and a buyout option.According to Rodin CEO Adam Rosenberg, HDAC2 is up-regulated in the brains of AD patients, and studies by the company's

Read the full 690 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE